RD

ART, a Chevron, Grace Joint Venture, Launches Catalyst System to Produce Renewable Diesel, Sustainable Aviation Fuel from 100% Renewable Sources

Retrieved on: 
Mardi, juillet 25, 2023
U.S. Department of Energy, Office of Inspector General, Transport, ART, CLG, CVX, Grace, U.S. Department of Defense Strategy for Operating in Cyberspace, NYSE, RD, SAF, Renewable energy

The announcement comes against the backdrop of significant demand growth for renewable transportation fuels.

Key Points: 
  • The announcement comes against the backdrop of significant demand growth for renewable transportation fuels.
  • “ENDEAVOR™ catalysts are the culmination of an extensive R&D program and have already demonstrated top-tier performance in several refinery applications,” said Nathan Ergonul, ART’s Managing Director.
  • The ENDEAVOR™ catalyst system consists of EnRich® guard and hydrotreating catalysts and includes Chevron's industry leading EnHance™ isomerization catalysts, all developed specifically for processing renewable feeds.
  • Renewable fuels such as RD and SAF are expected to play a key role in the decarbonization of heavy-duty transportation.

U.S. Energy™ Expands its Freight Service & Refined Products Offerings in Las Vegas

Retrieved on: 
Mercredi, juillet 19, 2023
Growth, Edgewood, Steel, Movement, RD, SAF, Rail freight transport

“We’re excited to leverage this property to supply refined products to the region and also expand our transloading and freight service offering," shared Mike Koel, president of U.S. Energy.

Key Points: 
  • “We’re excited to leverage this property to supply refined products to the region and also expand our transloading and freight service offering," shared Mike Koel, president of U.S. Energy.
  • “Coordinating the movement of energy throughout the supply chain has been a core capability of ours for more than 70 years.
  • Using this strength to help customers move their products throughout the region is something we look forward to."
  • The onsite bulk plant delivers additional refined product storage capacity, rack access, and room for growth to accommodate specialty products such as avgas, jet fuel, and boutique gasoline blends.

Kyowa Hakko's IMMUSE™ Postbiotic Wins Inaugural "Microbiome Modulation" Industry Award

Retrieved on: 
Vendredi, juillet 14, 2023
Drink, Powder, Lactococcus lactis, Clinical trial, Christian democracy, NK, MBA, Cell, RD, Doctor of Philosophy, PDC, Audio and Radio Industry Awards, Kyōwa, Capsule, Kyowa Kirin, Food and Drug Administration, Immune system, Ingredient, Food, Disease, Pharmaceutical industry, Vaccine, Plasma

NEW YORK, July 14, 2023 /PRNewswire-PRWeb/ -- Kyowa Hakko USA is thrilled to announce that our groundbreaking product, IMMUSE™ postbiotic for immune health, has been honored as the inaugural recipient of the the Ingredient of the Year: Microbiome Modulation category in the esteemed annual awards by NutraIngredients-USA.

Key Points: 
  • Kyowa Hakko's IMMUSE™ Postbiotic Wins Inaugural "Microbiome Modulation" Industry Award.
  • IMMUSE™ is a clinically researched Lactococcus lactis strain Plasma (LC-Plasma) that uniquely activates the immune system and plasmacytoid dendritic cells (pDCs) to support healthy days*.
  • Thirty published studies, including 15 human trials, support IMMUSE™'s novel mechanism of action.
  • Kyowa Hakko's parent company, Kirin Holdings Co., Ltd. discovered IMMUSE™'s unique mechanism of action.

Ocular Therapeutix™ Announces Appointment of New Board Member

Retrieved on: 
Mercredi, juillet 12, 2023
Opus, University, Refractive surgery, Doctor of Philosophy, Emeritus, Stanford University, Eye, Himalayan Cataract Project, Research, ASCRS, RD, Ophthalmic, The Many Ghosts of Doctor Graves, Grave, Ophthalmology, OWL, Alcon, Brown University, ISCB Senior Scientist Award, Akorn, FFB, Cataract, Therapy, Society, Pharmaceutical industry, Management, Psychology

BEDFORD, Mass., July 12, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced the appointment of Adrienne L. Graves, Ph.D., to its Board of Directors.

Key Points: 
  • BEDFORD, Mass., July 12, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced the appointment of Adrienne L. Graves, Ph.D., to its Board of Directors.
  • A visual scientist by training and a global industry leader in ophthalmology, Dr. Graves brings extensive experience to her role.
  • Prior to Santen, she spent 9 years at Alcon, joining as Senior Scientist to establish Alcon’s first Retinal Electrophysiology Laboratory.
  • She is a Visionary Innovation Mentor at the Ophthalmic Innovation Program at Stanford University.

Orphan Drugs and Rare Diseases Conference: Life-saving Therapies, Critical Issues, and Strategies to Enhance Orphan Drug Development in near future (London, United Kingdom - October 9-10, 2023) - ResearchAndMarkets.com

Retrieved on: 
Vendredi, juillet 7, 2023
Health, Pharmaceutical, Orphan Drug Act of 1983, Drug development, Marketing, University, Research, RD, ODA, Rare, Patient, Artificiality, Knowledge, Diagnosis, Digital, Artificial intelligence, Next Generation, Conference, Pharmaceutical industry

The 4th Annual Orphan Drugs and Rare Diseases Conference, to be held on October 9-10 in London, UK, aims to provide a valuable and broad platform to discuss recent advances in the development of life-saving therapies, critical issues, and strategies to enhance orphan drug development in near future.

Key Points: 
  • The 4th Annual Orphan Drugs and Rare Diseases Conference, to be held on October 9-10 in London, UK, aims to provide a valuable and broad platform to discuss recent advances in the development of life-saving therapies, critical issues, and strategies to enhance orphan drug development in near future.
  • With the enforcement of the 1983 Orphan Drug Act (ODA), manufacturers are obliged to scale production to treat rare/orphan diseases, leading to a drastic advancement in the landscape of orphan drugs.
  • The present-day challenges, including constrained resources, disease severity, limited patient access, and a lack of available knowledge in rare diseases, necessitate the discovery of innovative solutions to hasten orphan drug development.
  • Participate in discussions with experts on how to tackle the critical issues shaping the future of orphan drugs.

Equip’s Virtual Eating Disorder Treatment Exhibits Exceptional Patient Outcomes, Breaks Barriers to Care

Retrieved on: 
Jeudi, juin 29, 2023
Insurance, Medicaid, Depression, Eating disorder, Anxiety, Quality of life, Work, Patient, Child, SAN, The Act to Obliging the Government to Provide Comprehensive Support to the Oppressed Palestinian People, Policy, Caregiver burden, Caregiver, Nursing, Pharmaceutical industry, Equip, RD, Research

According to the report, 81 percent of Equip patients reached or maintained their target weight within the first year of care – signaling renourishment – a critical component of eating disorder treatment for many patients.

Key Points: 
  • According to the report, 81 percent of Equip patients reached or maintained their target weight within the first year of care – signaling renourishment – a critical component of eating disorder treatment for many patients.
  • Equip’s virtual treatment also significantly increased quality of life, and patients saw their symptoms reduced by at least 50 percent in their first five months of treatment.
  • After six months, fewer patients and caregivers reported missing school or work, allowing them to live their lives without the interruption of an eating disorder.
  • Equip’s model breaks down the significant care barriers in today’s current treatment landscape, including cost, geographic access, and stigma.

FloraWorks Announces Scientific Breakthrough in Natural Sleep Aids: First-Ever Double-Blind, Randomized, Placebo-Controlled Clinical Trial Discovers CBN Effective for Sleep

Retrieved on: 
Mercredi, juin 28, 2023
Melatonin, Obesity, Sleep, Cannabinoid, Quality of life, Research, CBN, FDA, Clinical, Pharmaceutical industry, Dietary supplement, RD, Doctor of Philosophy, Cannabinol

Independently Conducted Trial by Radicle Science Finds Florworks's Flagship TruCBN; Showed a Significant Improvement in Sleep When Compared to Placebo

Key Points: 
  • The group taking 4 mg melatonin also showed a significant improvement in sleep compared to placebo.
  • The group taking 50 mg of TruCBN™ had slightly better sleep improvements compared to 4 mg of melatonin.
  • The groups taking 25 mg and 100 mg of TruCBN™ had marginally significantly better sleep improvements compared to placebo.
  • 50 mg of TruCBN™ delivered better sleep outcomes than 25 mg or 100 mg, which is the first clinical trial data to suggest TruCBN™ may have a U-shaped dose-response curve for sleep.

The Dairy Alliance Redefines the Role of Milk at the Peachtree Health & Fitness Expo

Retrieved on: 
Mardi, juin 27, 2023
Georgia World Congress Center, Electrolyte, MLS, NFL, CSCS, Food, Diet, Peachtree Road Race, Health, Meal, CSSD, Congress Center, Milk, Athlete, NSCA, NBA, MLB, Water, Carbohydrate, Sport, Kenneth Blaxter (animal nutritionist), Hunger, Dietary supplement, Dairy, RD, Expo, Atlanta, Publix, Exercise

ATLANTA, June 27, 2023 /PRNewswire/ -- Publix is partnering with The Dairy Alliance, a nonprofit redefining the vitality of milk's advancements in personal performance, by showing up at the Peachtree Health & Fitness Expo presented by Publix at the Georgia World Congress Center in Atlanta, with 4,000 bottles of milk to giveaway. The Dairy Alliance and Publix are working together to educate attendees and racers at the Expo on how they can achieve their personal best by drinking dairy milk.

Key Points: 
  • The Dairy Alliance and Publix are working together to educate attendees and racers at the Expo on how they can achieve their personal best by drinking dairy milk.
  • Researchers credit milk's natural electrolytes, carbohydrates, and high-quality protein for its effectiveness that surpasses water and sports drinks.
  • "At Publix, we're honored to team up with the Dairy Alliance to support the Atlanta Community Food Bank.
  • For more information about the nutritional benefits of milk, dairy recipe ideas, and more, visit www.thedairyalliance.com .

FoodMinds Announces upwaRD™ Class of 2023

Retrieved on: 
Mardi, juin 27, 2023
Social Media, Professional Services, Consumer, Other Education, Food, Beverage, Fitness & Nutrition, Education, Retail, Nursing, Women, Communications, Health, Consulting, Insulin resistance, CNAME record, Public, Policy, Multimedia, Nutrition education, RDN, Movement, Pulse, Athlete, Nutritionist, MPH, Social media, Management, Dietary supplement, LDN, RD

FoodMinds, a leading global food and nutrition affairs consultancy has announced its 2023 upwaRD™ honorees.

Key Points: 
  • FoodMinds, a leading global food and nutrition affairs consultancy has announced its 2023 upwaRD™ honorees.
  • View the full release here: https://www.businesswire.com/news/home/20230627515888/en/
    FoodMinds' 2023 upwaRD Winners (Graphic: FoodMinds)
    FoodMinds employs more than 20 RDNs and is committed to career development in the field.
  • “At FoodMinds, we pride ourselves in our ability to establish connections with emerging influencers positively transforming the food and nutrition landscape,” added Chelsea Elkin , MS, RD, senior director, FoodMinds, and upwaRD™ program lead.
  • “Our 2023 upwaRD™ class have strong reach and impact among their peers and with followers across their digital networks, channels and platforms.”

Goode Health Introduces Expert Panel of Medical Advisors

Retrieved on: 
Lundi, juin 26, 2023
News, Fox News, Exercise, North Carolina Research Campus, Nutrition, Doctor of Public Health, University, Diet, Boston Children's Hospital, CLT, Harvard University, CNSC, FACSM, NBC News, SCD, Department of Biology, University of Oxford, Grain boundary strengthening, Medicine, Private practice, Research, MIT, CBS, CNN, Appalachian State University, Trial of the century, Your Very Good Health, Harvard Medical School, Science, Name, Book, Discovery, Public health, Polyphenol, Publication, MD, Karolinska Institute, RIMM, Harvard T.H. Chan School of Public Health, Micronutrient, Hospital, Health, Massachusetts General Hospital, Epidemiology, Arnot, Diabetes, Flexner Report, Nursing, RD

The company's team of experts includes two on-staff experts and three consulting advisors:

Key Points: 
  • The company's team of experts includes two on-staff experts and three consulting advisors:
    Bob Arnot, MD, is the Chief Medical Officer for Goode Health.
  • Arnot's extensive experience in the medical and health professions makes him one of the most recognized names in the field.
  • "I'm looking forward to contributing to Goode Health as we develop innovations to optimize health and promote well-being in a way that makes it accessible, affordable and simple."
  • Alyssa Paglia, RD, CLT, is the Director of Nutrition for Goode Health.